Alfredo Lozada/LinkedIn
Sep 11, 2026, 09:51
Alfredo Lozada: Pelacarsen Lowers Lp(a), But Does It Lower CV Risk?
Alfredo Lozada, Founder of Clinica del Colesterol at Cholesterol Clinic, shared a post on LinkedIn:
“Futility of Pelacarsen in the Lipoprotein(a) HORIZON !!
8,323 people with Lpa and CV disease. Designed to prove a reduction CV events .
Pelacarsen lowered Lp(a), but the study did not reduce CV Events.
- Important information, has not been presented. For patients, the message is clear: this announcement does not change the genetics & management of Lp(a). For clinicians, keep driving LDL-C to target, blood pressure, and managing risk factors.
- Maybe patients need to start reducing Lpa much earlier to get benefit. The Diminishing Returns graph & theory attached, shows that earlier Tx is needed !! As with inflammation you need to fight the fire, not the ashes !!
We wait the data release from other ongoing outcome trials to understand the next steps in CV prevention. What will you do at home?”
Stay updated with Hemostasis Today.
-
Oct 28, 2026, 14:56Elizabeth Shirley: COVID-19 Vaccines, Spike Protein and Nitric Oxide Bioavailability
-
Oct 28, 2026, 14:39David Ledger: Anticoagulation Advances as Factor XIa Inhibition Reaches a New Milestone
-
Oct 28, 2026, 14:37Advancing Liver Health in Haemophilia Care – EAHAD
-
Oct 28, 2026, 14:34The Changing Landscape of Anticoagulant Therapy – ISTH
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters